Lexapro and other new products key to Mochida's mid-term growth
This article was originally published in Scrip
Executive Summary
Mochida is looking to new products to boost its consolidated sales by 26% to ¥100 billion ($1.3 billion) over the next three years, despite looming competition for its top-selling drug.